TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30758216
Drug: Vehicle formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle formulation (chitosan and PEG 400)
Study: 27585808
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help intervention (based on problem-solving therapy)
Study: 26470874
Drug: Single ascending
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of 20(S)-ginsenoside Rg3 (10-60 mg)
Study: 26470874
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 20(S)-ginsenoside Rg3 (30 mg for 15 days)
Study: 17612905
Drug: Single-tablet combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet combination therapy
Study: 10634963
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion
Study: 2248077
Drug: Moclobemide 300‐500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300‐500 mg daily for 4 weeks
Study: 2248077
Drug: Moclobemide 150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 150‐300 mg daily for 6 weeks
Study: 2248077
Drug: Mianserin 75‐125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 75‐125 mg daily for 4 weeks
Study: 2248077
Drug: Maprotiline 75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 75‐150 mg daily for 6 weeks
Study: 26490018
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink containing Lactobacillus casei Shirota, administered twice a day for 4 weeks.
Study: 26490018
Drug: Placebo drink,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink, administered for 4 weeks.
Study: 24626000
Drug: Theophyline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophyline (4 mg/kg IV loading dose, followed by 200 mg orally three times daily for four days)
Study: 20550483
Drug: Orodispersible tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orodispersible tablets (ODTs) incorporating PEG solid dispersion of meloxicam (MLX)
Study: 20550483
Drug: Marketed immediate
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed immediate release MLX tablet
Study: 20386003
Drug: Enhanced depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced depression treatment (problem-solving therapy and/or pharmacotherapy, then a stepped-care approach)
Study: 12952293
Drug: IL-4 Pseudomonas
Normalized name: Il-4 pseudomonas toxin fusion protein (il-4(38-37)-pe38kdel)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-4 Pseudomonas exotoxin (NBI-3001) administered intratumorally via convection-enhanced delivery at doses of 6 microg/ml x 40 ml, 9 microg/ml x 40 ml, 15 microg/ml x 40 ml, or 9 microg/ml x 100 ml.
Study: 11028576
Drug: Intracutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injection
Study: 8630719
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg qd
Study: 1428726
Drug: Difluorodeoxycytidine (dFdC)
Normalized name: 2',2'-Difluorodeoxycytidine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Difluorodeoxycytidine (dFdC) administered by 30 minute infusion at doses of 5-90 mg/m2
Study: 1428726
Drug: Difluorodeoxycytidine (dFdC)
Normalized name: 2',2'-Difluorodeoxycytidine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Difluorodeoxycytidine (dFdC) administered by 5 minute bolus at doses of 30-150 mg/m2
Study: 29152718
Drug: KLOX BioPhotonic
Normalized name: Kloxxado
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KLOX BioPhotonic System (LED blue light phototherapy with photo-converter chromophores), treated hemiface, 12 weeks total (6 weeks treatment + 6 weeks follow-up)
Study: 29152718
Drug: Control hemiface
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control hemiface (untreated during Main trial), received 6 weeks of treatment (twice weekly)
Study: 26692004
Drug: Henagliflozin 5
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 5 mg/day
Study: 26692004
Drug: Henagliflozin 10
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 10 mg/day
Study: 26692004
Drug: Henagliflozin 20
Normalized name: bexagliflozin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 20 mg/day
Study: 20211542
Drug: Arthrocentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis plus intra‐articular injection of tenoxicam
Study: 15914614
Drug: Oral angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral angiotensin II receptor blocker (ARB)
Study: 10902989
Drug: Energy and
Normalized name: Energy And Endurance Testosterone UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy and micronutrient supplement (1171 kJ + 12 mg iron)
Study: 10902989
Drug: Energy and
Normalized name: Energy And Endurance Testosterone UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy and micronutrient supplement (209 kJ + 12 mg iron)
Study: 10902989
Drug: Energy and
Normalized name: Energy And Endurance Testosterone UP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy and micronutrient supplement (104 kJ)
Study: 8770304
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of ketorolac administered via Jackson‐Pratt drain or intravenously
Study: 8770304
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered via Jackson‐Pratt drain or intravenously
Study: 30485400
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at weeks 0 and 4 and every 8 weeks thereafter
Study: 30485400
Drug: adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 80 mg at week 0, 40 mg at week 1, and 40 mg every 2 weeks thereafter
Study: 20462041
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of midazolam (0.04 mg/kg)
Study: 20462041
Drug: Combined epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined epidural infusion and EA
Study: 12419082
Drug: sequential estradiol‐norethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential estradiol‐norethisterone acetate regimen
Study: 10993623
Drug: Minimum 5-day
Normalized name: sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum 5-day IV antibiotic course (Group 1)
Study: 10993623
Drug: No minimum
Approvals — FDA: no, EMA: no, PMDA: no
Description: No minimum IV antibiotic requirement (Group 2)
Study: 1459376
Drug: Ethanol by
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol by ingestion (95%‐0.84 ml/kg)
Study: 28119496
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with 125 mg of bosentan twice daily plus 10 μg of iloprost 4‐6 times/d
Study: 28119496
Drug: Bosentan monotherapy
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan monotherapy with 125 mg of bosentan twice daily
Study: 28119496
Drug: Iloprost monotherapy
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost monotherapy with 10 μg of iloprost 4‐6 times/d
Study: 23283501
Drug: Oral-lipid-tolerance tests
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-lipid-tolerance tests (OLTTs)
Study: 12971730
Drug: Nocturnal BCAA
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal BCAA administration
Study: 12971730
Drug: Daytime BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime BCAA administration
Study: 10755543
Drug: MMF 1
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1 g/day
Study: 10755543
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g/day
Study: 9294478
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg days -1, 0, 1, 7, 8, and 9 of each cycle)
Study: 24349598
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (2 mg/kg)
Study: 20107293
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies for PHN pain relief
Study: 18390971
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m² day 1 followed by 250 mg/m² weekly) plus Irinotecan (350 mg/m² every 3 weeks)
Study: 16797948
Drug: Sustained-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release metformin hydrochloride pellets (F-2, F-3)
Study: 16797948
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release metformin tablet (Glucophage)
Study: 14505991
Drug: Phytosterol ester-enriched
Normalized name: phytosterol esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol ester-enriched vegetable oil (0.45 g/day as free sterol)
Study: 14505991
Drug: Control vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vegetable oil (0.04 g phytosterol as the major free sterol)
Study: 10811340
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and ribavirin (3 million units of alpha‐interferon three times weekly with 1000 mg of ribavirin daily)
Study: 10811340
Drug: Interferon and
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon and amantadine (3 million units of alpha‐interferon with 200 mg of amantadine daily)
Study: 9023837
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin-containing regimens followed by radiotherapy
Study: 9023837
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after radiotherapy
Study: 7816256
Drug: Desferrioxamine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine 15 mg/kg administered 1 hour before dialysis
Study: 7816256
Drug: Desferrioxamine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine 15 mg/kg administered 44 hours before dialysis
Study: 2897784
Drug: Nizatidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (300 mg, once daily at bedtime)
Study: 2897784
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg, once daily at bedtime)
Study: 21337296
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus resource activation (RFCBT)
Study: 19417872
Drug: Xylitol lozenges
Normalized name: xylitol Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Study: 19417872
Drug: Sorbitol lozenges
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol lozenges (5 pieces/day, 2 g each) for 4 weeks
Study: 15188351
Drug: MRA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA (8 mg/kg body weight)
Study: 15188351
Drug: MRA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA (4 mg/kg body weight)
Study: 8521306
Drug: Oral transmucosal
Normalized name: Thrive, 2 mg oral transmucosal gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms.kg-1
Study: 2334454
Drug: ibopamine solution
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibopamine solution 1%
Study: 2334454
Drug: tropicamide solution
Normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tropicamide solution 1%
Study: 2334454
Drug: ibopamine solution
Normalized name: ibopamine
DrugBank: Ibopamine (DB13316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibopamine solution 0.25% and 0.50%
Study: 103404
Drug: Meglumine iotroxate
Normalized name: Meglumine iotroxate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine iotroxate (3.6 g iodine)
Study: 103404
Drug: Meglumine iodoxamate
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meglumine iodoxamate (5.3 g iodine)
Study: 103404
Drug: Meglumine ioglycamate
Normalized name: meglumine ioglycamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine ioglycamate (5.3 g iodine)
Study: 18646005
Drug: interesterified butter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: interesterified butter blend with fish oil (352 mg n‐3 long‐chain PUFA)
Study: 10949982
Drug: Teicoplanin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (10 mg x kg(‐1) x d(‐1))
Study: 10949982
Drug: Vancomycin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (40 mg x kg(‐1) x d(‐1)) plus ceftazidime and netilmicin
Study: 1684749
Drug: Methyldopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (500 mg to 1 g daily)
Study: 1684749
Drug: Rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1 to 2 mg daily)
Study: 24646429
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention (BI) for medication-overuse headache (MOH)
Study: 17265549
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (manual needle stimulation of 19 acupoints, 30 min sessions, 10 sessions over a year)
Study: 16105122
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole initially and maintenance therapy with a standard dose H(2)‐RA
Study: 16105122
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of lansoprazole initially and maintenance therapy of 15 mg lansoprazole
Study: 16105122
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of lansoprazole once daily for 16 weeks
Study: 20723187
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation (100,000 iu) along with antibiotics
Study: 20723187
Drug: Placebo along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo along with antibiotics
Study: 14629655
Drug: Delipidated acid-treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delipidated acid-treated M. vaccae (0.4 mg first dose, 0.8 mg second dose)
Study: 8760546
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen therapy (HBO) - 100% O2 at 2.5 ata for 90 minutes, twice daily, over 6 days
Study: 8760546
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 21% O2 at 1.1 ata for 90 minutes, twice daily, over 6 days
Study: 8760546
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen therapy (HBO)
Study: 1750819
Drug: Treatment (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (exact intervention not specified)
Study: 29098247
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser as an adjunctive to scaling and root planning (SRP)
Study: 21911313
Drug: Cryotherapy (holding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (holding ice cubes in mouth before, during, and after chemotherapy)
Study: 19434929
Drug: High-dose IFN‐α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN‐α‐2b induction therapy combined with amantadine and ribavirin for 6 weeks followed by weekly pegylated IFN‐α‐2b for 24 or 48 weeks
Study: 19434929
Drug: High-dose IFN‐α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN‐α‐2b induction therapy
Study: 17103193
Drug: 2 g-IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g-IVIG
Study: 17103193
Drug: 1 g-IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g-IVIG
Study: 17103193
Drug: 1 g-IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g-IVIG with additional IVIG
Study: 11429399
Drug: Amiodarone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (oral administration for 4 weeks)
Study: 9599521
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (two inhalations of 1000 micrograms)
Study: 12511310
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone (0.6 mg/kg)
Study: 2744928
Drug: Exercise at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise at 40% of maximal workload with carbohydrate feeding (25% maltodextrin-fructose solution) for 2.5 hours
Study: 2744928
Drug: Rest for
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest for 2.5 hours with carbohydrate feeding (25% maltodextrin-fructose solution)
Study: 1253811
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion before fasting and on day 4 of fasting
Study: 1253811
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment (300 mg/day p.o.) on days 6 to 8 of the fast
Study: 1253811
Drug: Glucose load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose load (100 g) on day 7
Study: 24482945
Drug: Intramuscular ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ACTH stimulation test using Acton Prolongatum (25 units injected intramuscularly)
Study: 15910892
Drug: Ajulemic acid
Normalized name: Ajulemic acid
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajulemic acid (AJA) 40 mg and 80 mg daily
Study: 14522763
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 400 mg twice daily for 6 months
Study: 14522763
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 6 months
Study: 10945510
Drug: Naftidrofuryl 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl 600 mg/d
Study: 8803646
Drug: L-fenfluramine
Normalized name: DL-Fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-fenfluramine
Study: 8803646
Drug: D-amphetamine +
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine + L-fenfluramine
Study: 6418300
Drug: Real electroconvulsive
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real electroconvulsive therapy
Study: 6418300
Drug: Simulated electroconvulsive
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated electroconvulsive therapy
Study: 29127547
Drug: Magnesium and
Normalized name: Calcium, Magnesium and Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium and zinc co-supplementation (250 mg of magnesium oxide plus 220 mg of zinc sulfate containing 50 mg zinc)
Study: 30336805
Drug: ZX008 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 0.8 mg/kg
Study: 30336805
Drug: STP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: STP regimen (stiripentol 3,500 mg, clobazam 20 mg, valproate 25 mg/kg, max. 1,500 mg)
Study: 30336805
Drug: ZX008 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZX008 0.8 mg/kg + STP regimen
Study: 14614647
Drug: Metformin, thiazolidinediones,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, thiazolidinediones, and acarbose
Study: 14614647
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and thiazolidinediones with sulphonylureas or meglitinides
Study: 9099461
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant CAF chemotherapy
Study: 9099461
Drug: Standard-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose adjuvant CAF chemotherapy
Study: 9099461
Drug: Low-dose adjuvant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adjuvant CAF chemotherapy
Study: 8402326
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K (1 mg/day) for 2 weeks
Study: 8402326
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K (1 mg/day) for 3 months
Study: 8402326
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K (1 mg/day) for 3 months in fast losers of urinary calcium
Study: 3081221
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg twice daily for six weeks)
Study: 27183454
Drug: Training general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training general practitioners (GPS) in optimizing HF medication
Study: 18544642
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment for 10 weeks
Study: 16447591
Drug: Periprostatic plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic plexus anesthesia (PPA) with 10 cc lidocaine, 2% diluted 50%
Study: 8791132
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and NSAIDs
Study: 6349289
Drug: Health motivation
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health motivation treatment (self-management skills, film model, verbal commitment, discussion of costs and benefits)
Study: 6349289
Drug: Health motivation
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health motivation treatment
Study: 30308287
Drug: Daily drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily drinking